

[Share Price >](#)[Contact us](#)

MIDATECH PHARMA

[ABOUT US](#)[R&D](#)[TECHNOLOGIES](#)[PRODUCTS](#)[PARTNERSHIPS](#)[INVESTORS](#)[MEDIA](#)

News | News Release

[News](#)[Current News](#)[News 2016](#)[News 2015](#)[News 2014](#)[News 2013](#)[News 2012](#)[News 2011](#)[News 2010](#)[News 2008](#)

Jan 2, 2018

Midatech enters into a Loan Agreement with MidCap Financial

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, is pleased to announce that it has entered into a four-year senior secured loan agreement with MidCap Financial of up to \$15 million (the "Facility").

Midatech has received an initial tranche of \$7 million. The issuance of further tranches under the Facility is dependent on clinical development milestones set out for MTD201 and MTX110. The funds will be used to support progression towards these and other value-driving product milestones.

Commenting on the agreement, Dr Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "This agreement allows us to continue the clinical development of key products. With the extensive due diligence that was required, it also indicates significant support in Midatech's future. With our lead programmes heading towards potentially significant, value-driving inflection points in 2018, and the continued progress of our R&D pipeline and US commercial activities, this is an exciting time for the business."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

[Close](#)[Home](#)[T&Cs](#)[Privacy Policy](#)[Sitemap](#)[Careers](#)

© Copyright 2018 Midatech Pharma PLC

We use cookies to ensure we give you the best experience on our website

[Accept](#)[Privacy Policy](#)